Business Wire

Zayed Sustainability Prize 2023 Demonstrates Global Reach and Impact with over 4,500 Submissions

15.9.2022 03:27:00 EEST | Business Wire | Press release

Share

Following a successful 4-month submissions phase, the Zayed Sustainability Prize, the UAE's pioneering global award for recognising excellence in sustainability, has officially closed entries for its 2023 awards cycle. Over 4,500 applications were received across the five Prize categories of Health, Food, Energy, Water and Global High Schools, from a record 152 countries, demonstrating the Prize’s growing global reach and impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005418/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Zayed Sustainability Prize 2023 receives more than 4,500 submissions globally (Graphic: AETOSWire)

The Zayed Sustainability Prize winners will be announced at the 2023 Zayed Sustainability Prize Awards Ceremony that will be held on January 16, 2023 as part of Abu Dhabi Sustainability Week.

The Prize witnessed a 13% increase in submissions compared to last year from small and medium-sized enterprises (SMEs), nonprofit organisations and high schools. Total submissions from SMEs increased across all categories, underscoring a rising trend that SMEs are putting sustainability at the top of their agenda.

H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Director General of the Prize, said: “For the last 14 years the Zayed Sustainability Prize has incentivised practical solutions to global challenges that deliver tangible impact at a community level around the world. Inspired by the commitment to sustainable development and humanitarian legacy of Sheikh Zayed bin Sultan Al Nahyan, the Prize has improved the lives of 370 million people in 151 countries to date. This year, we have seen applications from a record number of countries across every category from health, food, energy, water and global high schools. I'm excited to see what creative solutions this year’s applicants will bring to the table, particularly as the UAE prepares to host COP 28 next year.”

“Given that we want to leverage COP 28 as a platform for inclusivity and practical outcomes, I am confident that the Prize can help to deliver social and economic progress from across the private sector, small business community and an increasingly active and engaged younger generation,” he added.

This year’s submissions were more diverse than ever before, revealing climate change’s impact on every country across every continent, and reflecting a growing awareness that urgent climate action is critical to meet global net zero carbon goals by mid-century.

More submissions received this year came from developing nations in Sub-Saharan Africa, South Asia, East Asia, Latin America, the Middle East, and North Africa, which is an important indication of the growing participation of developing countries in the fight against climate change.

The top submitting countries included Kenya, India, China, Egypt, Brazil and the United States. By receiving submissions from a wide range of geographies, the Prize is better equipped to deliver on its mission of driving impactful, innovative, and inspiring sustainable and humanitarian development around the world.

The Food (1,426) and Health (946) categories attracted the greatest number of submissions, followed by Energy (736) and Water (601), while the Global High Schools category received 829 submissions.

In the Food category, which received nearly 20% increase in submissions compared to last year, many entries presented solutions aimed at achieving sustainable food production to address rising food insecurity and malnutrition in a world threatened by climate change.

In the Health category, several entries address the weaknesses of the healthcare systems exposed by the Covid-19 pandemic, and offer solutions that provide more resilient, inclusive, accessible, and sustainable healthcare services to people most in need.

In the Energy category, the Prize received numerous entries focused on improving sustainable energy access in vulnerable communities, supporting United Nations Sustainable Development Goal 7, affordable and clean energy for all, and driving the low-carbon energy transition.

Finally, in the Water category, a number of entries offered solutions aimed at addressing the clean water production, climate change, and water resource management challenges faced around the world, and particularly in developing nations.

The number of submissions received from high schools grew by 55% compared to last year, which is especially encouraging and a testament to young people’s growing awareness of the challenges and risks presented by the climate crisis and of the opportunity to lead on sustainable development. Entries in the Global High Schools category proposed waste management solutions, clean energy systems, and food systems like hydroponics and aquaponics, reflecting the students’ innovative thinking and careful consideration of projects most suited for their local communities.

Following the close of submissions, the Prize now enters the evaluation stage. All entries will now be shortlisted by an independent research and analysis consultancy. A Selection Committee comprised of globally renowned industry experts will then assess the qualified entries and shortlist the candidates. The third and final tier of the evaluation process is the Jury, which will convene in October, to unanimously elect the winners in each category.

Since its launch in 2008, the US$3 million Prize has, directly and indirectly, transformed the lives of over 370 million people around the world. Its global impact continues to grow, as it further catalyses humanitarian outreach and sustainable development. Each winner in the Health, Food, Energy, and Water categories receive US$600,000 to expand the scope and scale of their sustainability solution(s), while the Global High Schools category has six winners, representing six world regions, with each winner receiving up to US$100,000.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Baha Haroun
Baha.haroun@bcw-global.com

Reem Diab
Reem.Diab@bcw-global.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye